Effects of Acetazolamide and CO2 Inhalation on Exercise-Induced Periodic Breathing in Heart Failure

This study is currently recruiting participants.

Verified by Centro Cardiologico Monzino, August 2007

First Received: August 16, 2007 No Changes Posted

Sponsor:	Centro Cardiologico Monzino
Information provided by:	Centro Cardiologico Monzino
ClinicalTrials.gov Identifier:	NCT00517426

Purpose

To evaluate the effects of CO2 inhalation and acetazolamide treatment on exercise-induced periodic breathing in patients with chronic stable heart failure.

Patients will be given CO2 (2%) during a constant workload exercise. Patients will be also evaluated by maximal cardiopulmonary exercise test without and with acetazolamide acute and chronic treatment.

Condition	Intervention	Phase
Chronic Heart Failure	Drug: acetazolamide	Phase IV

Study Type:	Interventional
Study Design:	Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study

Resource links provided by NLM:

MedlinePlus related topics: Exercise and Physical Fitness Heart Failure

Drug Information available for: Acetazolamide Acetazolamide sodium

U.S. FDA Resources

Further study details as provided by Centro Cardiologico Monzino:

Primary Outcome Measures:

Suppression of periodic breathing [ Time Frame: two days ]

Secondary Outcome Measures:

suppression of sleeping apnea [ Time Frame: two days ]

Estimated Enrollment:	20
Study Start Date:	July 2007
Estimated Study Completion Date:	August 2009

Intervention Details:

i.v. 500 mg of acetazolamide for the acute study and 500 mg of acetazolamide p.o. t.i.d. for two days

Eligibility

Ages Eligible for Study:	18 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

chronic heart failure in stable clinical condition
exercise-induced periodic breathing

Exclusion Criteria:

comorbidities
NYHA class IV

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00517426

Contacts

Contact: Piergiuseppe Agostoni, MD, PhD

+39.025800 ext 2299

piergiuseppe.agostoni@ccfm.it

Locations

Italy
Centro Cardiologico Monzino, University of Milan	Recruiting
Milan, Italy, 20138
Contact: Piergiuseppe Agostoni, MD, PhD +39.025800 ext 2299 piergiuseppe.agostoni@ccfm.it
Sub-Investigator: Mauro Contini, MD

Sponsors and Collaborators

Centro Cardiologico Monzino

Investigators

Principal Investigator:

Piergiuseppe Agostoni, MD, PhD

Centro Cardiologico Monzino

More Information

Publications:

Agostoni P, Bussotti M, Cattadori G, Margutti E, Contini M, Muratori M, Marenzi G, Fiorentini C. Gas diffusion and alveolar-capillary unit in chronic heart failure. Eur Heart J. 2006 Nov;27(21):2538-43. Epub 2006 Oct 6.

Study ID Numbers:	R77-CCM S79/407
Study First Received:	August 16, 2007
Last Updated:	August 16, 2007
ClinicalTrials.gov Identifier:	NCT00517426 History of Changes
Health Authority:	Italy: Ministry of Health

Keywords provided by Centro Cardiologico Monzino:

heart failure,
exercise
periodic breathing,
acetazolamide

Additional relevant MeSH terms:

Heart Failure
Heart Diseases
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Diuretics
Acetazolamide
Enzyme Inhibitors
Cardiovascular Agents

Pharmacologic Actions
Carbonic Anhydrase Inhibitors
Natriuretic Agents
Therapeutic Uses
Cardiovascular Diseases
Central Nervous System Agents
Anticonvulsants

ClinicalTrials.gov processed this record on February 08, 2010